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Objective: Probiotics have previously been shown to reduce the severity of atopic disease in infants and
children. However, the immunological changes induced by this treatment that might account for the
clinical improvement are still unclear. In this study, we examined the effect of Lactobacillus rhamnosus on
the clinical symptoms and medication use among children with established allergic rhinitis. We also
investigated the effect of probiotics on the white blood cell counts, red blood cell counts, platelet counts,
eosinophil counts, and IgE antibody levels.
Materials and Methods: Atopic children with current rhinitis received 4 109 colony forming units/g of
L rhamnosus (n¼ 98) or a placebo (n¼ 100). Both were given this daily as a powder mixed with food or
water. The SCORing Allergic rhinitis index (speciﬁc symptoms scores and symptom medication scores),
which measures of the extent and severity of allergic rhinitis, was assessed for each patient at the ﬁve
visits. These ﬁve scheduled visits were at 2 weeks before starting the treatment (Visit 0), at the beginning
of the treatment (Visit 1), then 4 weeks (Visit 2), 8 weeks (Visit 3), and 12 weeks (Visit 4) after starting
the treatment. The white blood cell, red blood cell, platelet, and eosinophil counts as well as the IgE
antibody levels of the individuals were evaluated before and after 3 months of treatment.
Results: The major outcome, indicating the efﬁcacy of L rhamnosus treatment, was no reduction in rhinitis
symptoms or drug scores. No signiﬁcant statistical differences were found between baseline and
3 months for the probiotic and placebo groups when any immunological and blood cell variable was
examined.
Conclusions: Our data demonstrates that L rhamnosus treatment neither reduced rhinitis symptom scores
nor altered immunological parameters in symptomatic children.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
All rights reserved.1. Introduction
Allergic rhinitis (AR) is a common childhood disease that often
persists into adulthood. The prevalence of childhood allergic
disease has increased dramatically in recent decades in many parts
of the world, including Taiwan [1]. The prevalence of reported
current symptoms of AR in Taiwanese children aged 6e8 years andMedicine, Buddhist Tzu Chi
ualien, Taiwan. Tel.: þ886 3
Lin).
ddhist Compassion Relief Tzu Chi13e15 years are 29.8% and 18.3%, respectively [1]. The causes of AR
are unknown but many cases, particularly in early childhood, are
associated with sensitization to food proteins. Children who are
atopic and develop dermatitis are at a signiﬁcantly increased risk of
developing atopic asthma and rhinitis in later childhood [2]. This
immune response includes both IgE antibodies and helper T cells
Type 2 (Th2), which are thought to contribute to inﬂammation in
the respiratory tract. Moreover, sensitization to indoor allergens
(e.g., dust mites, cats, and dogs) is strongly associated with AR.
Probiotics are deﬁned as products or preparations containing
viable numbers of microorganisms that are able to modify the
host’s microﬂora, thereby producing beneﬁcial health effects [3].Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline characteristics of the study population by study group
Baseline characteristics Group 1 Group 2
Number of patients 100 98
Mean age (yr) (SD) 8.0 (4.3) 8.1 (4.4)
Mean BW (kg) (SD) 27.6 (15.8) 28.2 (16)
Gender (M/F) 63/37 59/39
Family history of allergic disease 64 70
Rhinitis alone 51 57
Rhinitisþ asthma 48 40
Follow-up (mo) 7 7
Duration of disease (yr) (SD) 3.8 (0.5) 3.8 (0.3)
BW¼ body weight; SD¼ standard deviation.
Group 1 (placebo); Group 2 (LR).
R.-H. Jan et al. / Tzu Chi Medical Journal 23 (2011) 51e5452Two lines of argument have led to studies of the relationship
between bowel ﬂora and allergic disease. Firstly, lower counts of
Enterococci and Biﬁdobacteria in infancy have been found in atopic
versus nonatopic children and these differences precede sensiti-
zation [4,5]. The early colonization of the bowel with probiotic
bacteria, such as Enterococci and Biﬁdobacteria are hypothesized to
more effectively mature the gut mucosal immune system and
promote tolerance to nonbacterial antigens. Secondly, increased
gut permeability may lead to increased exposure to food antigens
and this has been associated with atopic dermatitis (AD) [6]. Pro-
biotics may decrease this permeability and thus decrease systemic
exposure to food antigens.
Isolauri et al [7] have previously reported an improvement in
the SCORing Atopic Dermatitis index of milk-allergic infants with
mild AD following probiotic-supplemented hydrolyzed whey
formula. Recently, Rosenfeldt et al [8] in a crossover study
demonstrated an improvement in SCORing Atopic Dermatitis index
in older childrenwith ADwhowere treated with probiotics, but the
improvement was only signiﬁcant for atopic children. Indeed,
Lactobacillus paracasei may improve the quality of life of adoles-
cents with perennial AR [9,10]. Some studies have supported the
effect of probiotics on rhinitis but the results remain controversial
[11,12]. Double-blind controlled studies are needed to clarify the
effects of probiotic bacteria on allergy-related disorders. We
examined the effect of probiotic treatment on atopic children with
rhinitis. Various speciﬁc clinical and immune parameters were
assessed in a panel of allergen-sensitive patients before and after
treatment and were compared with those from a matched group of
untreated (UT) allergen-sensitive patients.
2. Materials and methods
2.1. Patients
A total of 240 (120 male and 120 female) age-matched Derma-
tophagoides pteronyssinus (Dp), Dermatophagoides farinae (Df), or
dust-sensitive patients having perennial rhinitis and/or rhinitis
plus mild asthmawere recruited from February to March 2008. The
criteria for inclusion in the study were as follows: age below
18 years; history of perennial allergic symptoms for at least 3 years;
positive skin prick test for Dp, Df, or dust; and CAP positivity for Dp,
Df, or dust (more than Class 1). This study was approved by the
Research Ethics Committee of the Hualien Tzu-Chi General Hospital
and informed consent was obtained from all patients.
2.2. Balancing of experimental groups
The selected patients were randomized into two groups (con-
sisting of 120 UT patients and 120 patients treated with probiotics)
taking into account age, sex, medication scores, and type and
importance of symptoms.
2.3. Study design
The treatment group received 4109 colony forming units/g of
L rhamnosus (American Type Culture Collection 53103). The control
group received a placebo consisting of microcrystalline cellulose
that looked and tasted the same as the probiotic. The powder was
given once daily mixed in drink or food. A small number of the
older children took the powder as an opaque capsule. The viability
of the probiotic was testedmonthly. Both patients and investigators
were blind to the treatment groups. The study lasted for 12 weeks
and patients were followed up for 7 months to observe disease
manifestations. There were ﬁve scheduled visits: 2 weeks before
starting the treatment (Visit 0), at the beginning of the treatment(Visit 1), then 4 weeks (Visit 2), 8 weeks (Visit 3), and 12 weeks
(Visit 4) after starting the treatment. Parents received two phone
calls during the treatment period to check on progress and
compliance (6 and 9weeks after the beginning of the treatment). At
each visit, the severity of the child’s AR was evaluated using the
speciﬁc symptoms scores (SSS) and symptom medication scores
(SMS).
2.4. Questionnaire
All parents answered a questionnaire (Visit 0) about AR and the
allergic disease history of their child, the family’s history of allergic
diseases, and any current oral or topical medication.
During the 12 weeks of the study, parents were asked to
complete a weekly diary of medication use, health problems, and
the presence and severity of AR in the child to aid recall for the
questionnaire at the study visits. A ﬁnal questionnaire, which
covered medication, other allergic diseases, and changes in life
style or housing during the study, was completed at the end of
treatment.
2.5. Clinical evaluation
Both the treated and UT patients maintained a weekly diary of
allergic symptoms during the antigen exposure period. The SSS
recorded were nasal blockage, nasal itching, sneezing, rhinorrhea,
eye irritation and watering, wheezing, cough, and asthma. SMS
were calculated from patient diaries, as described in a previous
study [13]. Arbitrary scores were attributed to the drugs used
(0.5 points for each dose of nasal corticosteroids and 2 points for
each dose of antihistamine). Patients were instructed to use local
steroids plus antihistamines only if their symptoms did not
improve and to report each administration or variation of the initial
drug therapy in the diary. Patients were also instructed to stop their
medication at least 7 days before blood sampling. At each time
point (Time 0, 1, 2, 3, and 4 visits) of the study, patient self-
evaluation was carried out. Each one was asked for his/her overall
evaluation of the treatment based on categories of symptoms
gravity (from 0 to 9).
2.6. Immunological blood assessment
Blood samples were taken before and after treatment, to
examine markers for allergy, including total IgE, peripheral blood
cell counts, and blood eosinophil counts.
2.7. Statistical analysis
Statistical analysis was performed using paired and unpaired
Student t tests, as appropriate. A p value of less than 0.05 was
considered statistically signiﬁcant.
Fig. 1. Speciﬁc eye symptom clinical scores were evaluated for the two groups. The
study lasted 12 weeks. There were four scheduled visits: at the beginning of the
treatment (Visit 1), then 4 weeks (Visit 2), 8 weeks (Visit 3), and 12 weeks (Visit 4)
after starting the treatment. B¼ placebo; C¼ Lactobacillus rhamnosus. *p< 0.05
(vs. Visit 1 in each group).
Fig. 3. Speciﬁc lung symptom clinical score were evaluated for the two groups. The
study lasted for 12 weeks. There were four scheduled visits: at the beginning of the
treatment (Visit 1), then 4 weeks (Visit 2), 8 weeks (Visit 3), and 12 weeks (Visit 4)
after starting the treatment. B¼ placebo; C¼ Lactobacillus rhamnosus. *p< 0.05
(vs. Visit 1 in each group).
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3.1. Patients
The two groups did not differ in the terms of demographic
variables, age, body weight, gender, family history, medication
scores, and allergic symptoms. A total of 198 of the 240 enrolled
patients (82.5%) completed the study in the year 2008. All patients
were included in the safety analysis. The demographic information
is shown in Table 1.
3.2. Clinical efﬁcacy of the probiotic therapy in terms of allergic
symptoms
Clinical results for the 7 months follow-up were based on the
patient self-evaluation scores obtained at the beginning and after 4,
8, and 12 weeks of treatment. The SSS of the L rhamnosus treated
and UT patients at 4, 8, and 12weeks were not signiﬁcantly reduced
in comparison with those at Time 1 (the start of probiotic treat-
ment) in terms of eye, nose, and lung symptoms scores (Figs. 1e3).
We further determined whether or not the probiotic was able to
decrease drug use by analyzing the decrease in the drug score for
allergic disease between Visit 1 (beginning of the probiotic treat-
ment) and Visits 2, 3, or 4. There was no statistically signiﬁcant
change in medication scores for rhinitis for the two groups
throughout the study as shown in Fig. 4.
3.3. Blood and immunologic proﬁle
Because of sampling difﬁculties, blood was only collected from
103 patients. Blood cell counts, total IgE, and blood eosinophil
counts showed no differences between the placebo and probiotic
groups (Table 2).Fig. 2. Speciﬁc nasal symptom clinical score were evaluated for the two groups. The
study lasted for 12 weeks. There were four scheduled visits: at the beginning of the
treatment (Visit 1), then 4 weeks (Visit 2), 8 weeks (Visit 3), and 12 weeks (Visit 4)
after starting the treatment. B¼ placebo; C¼ Lactobacillus rhamnosus. *p< 0.05
(vs. Visit 1 in each group).4. Discussion
This study’s aim was to evaluate the effect of a probiotic on the
clinical response to allergens in randomized Dp, Df, or dust-
sensitive patients who had perennial rhinitis and/or asthma and
conjunctivitis. Although a signiﬁcant dropout rate (17.5%) was
observed during the study, this did not alter the representativeness
of the remaining members of the two groups as the baseline results
for the mean values for SSS and SMS measures of remaining group
members were similar to those of patients who dropped out. When
the situation examined after 3 months of probiotic treatment, the
L rhamnosus-treated group of patients did not show a clear-cut
reduction in nasal, lung, and eye symptoms compared with the
placebo group.
Bacteriotherapy with probiotic bacteria can affect the gut
microbial ﬂora in the host organism and thus have a beneﬁcial
effect on an individual’s health and well being [14,15]. L rhamnosus
(ATCC 53103), also called Lactobacillus GG, is an extensively studied
intestinal probiotic strain that has been shown to inﬂuence speciﬁc
and nonspeciﬁc immune responses in milk hypersensitive and
healthy patients [16]. Over the last few decades, some reports have
shown increasing enthusiasm for the potential health effects of
probiotics. However, clinical studies of the efﬁcacy of probiotics
have as yet shown no therapeutic effect with respect to AR [17] and
little or no beneﬁt as a therapy for AD [8,18].
So far, there has been only one published double-blind,
randomized, placebo-controlled trial and this showed no effect of
Lactobacillus GG on AR in children [17]. The results of this earlier
study needed to be interpreted with caution because the number of
patients involved was small (n¼ 36). Nonetheless, our ﬁndings
agree with this earlier result and our study used a considerably
larger group of patients (n¼ 240). The results of the present
double-blind and placebo-controlled study were also negative.Fig. 4. Symptom medication score differences between the different visits. Symptom
medication scores were evaluated for the two groups. The study lasted for 12 weeks.
There were four scheduled visits: at the beginning of the treatment (Visit 1), then 4
weeks (Visit 2), 8 weeks (Visit 3), and 12 weeks (Visit 4) after starting the treatment.
B¼ placebo; C¼ Lactobacillus rhamnosus. *p< 0.05 (vs. placebo group at each visit).
Table 2
Immunological and blood cell parameters throughout the study period
Group n Variables Before-After
Mean (SD) Median p
1 51 WBCs 1.14 (2.60) 1.21 0.071
51 Hb 0.04 (0.79) 0 0.915
51 Platelets 34.29 (48.68) 32 0.081
51 Eosinophils 0.93 (4.27) 0.1 0.555
51 IgE 150.5 (632.76) 35.85 0.375
2 52 WBCs 0.23 (1.90) 0.535 0.606
52 Hb 0.16 (0.60) 0.1 0.286
52 Platelets 15.13 (55.86) 12 0.296
52 Eosinophils 0.49 (3.51) 0.8 0.528
52 IgE 61.39 (284.82) 34 0.548
Hb¼ hemoglobin; SD¼ standard deviation; WBC¼white blood cell.
Group 1 (placebo); Group 2 (LR).
R.-H. Jan et al. / Tzu Chi Medical Journal 23 (2011) 51e5454Allergy and AR symptoms in the treatment groupwere not reduced
as compared with the control group.
On the other hand, there has been one study that suggests that
L rhamnosus may be useful and provide primary or secondary
prevention of atopic sensitization in an animal model [19]. It seems
probable that the probiotic therapy provided in the present study is
unable to bring clinically important relief in young children because
sensitization to Dp, Df, or dust has already occurred.
Various hypotheses have been proposed to explain the increase
in asthma and atopic disease that is apparent in industrialized
countries [20]. One hypothesis suggests that changes in the gut
microbial ﬂora, which have resulted from changes in diet and
hygiene, might be the cause [21]. In line with the hypothesis, it has
been shown that oral probiotic bacteriotherapy with L rhamnosus
does improve clinical symptoms by alleviating the intestinal
inﬂammation associatedwith food allergy in small children [22,23].
The gut ﬂora affects the Th1/Th2 lymphocyte balance [24]. We
further explored the effect of L rhamnosus in atopic children with
rhinitis by examining some speciﬁc immune and blood parameters
using this panel of allergen-sensitive patients before and after
treatment. However, no difference was found in these parameters
between the probiotic and placebo groups. This result agrees with
some previous studies [25e27]. The exact mechanism bywhich the
probiotic bacterial strain affects the regulatory mechanisms of the
immune responses is not yet clearly deﬁned. Further studies are
needed to clarify this point.
In conclusion, supplementation of children with AR with
L rhamnosus neither reduced rhinitis symptom scores nor altered
immunological parameters. These ﬁndings challenge the role of
probiotics in the treatment of childhood atopic disease. Therefore,
L rhamnosus cannot be generally recommended for primary treat-
ment of AR.References
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